Latest From Leela Barham
Lords Call For UK Government To Secure A ‘Growth’ Pricing Deal With Pharma
The House of Lords held a debate on the UK’s statutory drug pricing scheme as a way of drawing attention to the need for a voluntary price deal that can revive the international competitiveness of the life science industry.
What Role Is There for Patients In Managed Access Deals?
Market access deals can make or break routine access to new treatments. So what happens when patient-centricity and deal-making meet? Leela Barham looks at the experience in England.
The People Who Will Shape The UK’s New Drug Pricing Scheme
With talks on the next UK voluntary pricing scheme now well under way, the Pink Sheet looks at the industry and government negotiators who will be thrashing out the details in the coming months.
UK Parliamentarians Call For A New, Internationally Competitive Pricing System
Much-needed investment could be lost if the “uncompetitive” sales rebate rate is not reduced as part of talks on a new UK drug pricing scheme, some parliamentarians are warning.
Patient Groups Want More Say In Talks On New UK Pricing Deal
The Association of the British Pharmaceutical Industry has welcomed calls from three patient group umbrella organizations to be more involved as the UK government negotiates with the ABPI on a successor to the 2019 voluntary pricing scheme.
Legal Challenge Could Put UK Drug Pricing Deal At Risk
The body representing generics and biosimilars companies in the UK is seeking a seat at the table as negotiations on a new voluntary price scheme get under way.